AFT new FDA approval could be a shot in the arm

AFT new FDA approval could be a shot in the arm
Analyst sentiment is positive after FDA approval of Maxigesic IV. (Image: Hyloris Pharmaceuticals)
Ben Moore
AFT Pharmaceuticals had a bump in share price on Wednesday morning following approval of its intravenous post-operative pain relief drug by the United States Food and Drug Administration.Following the announcement of the approval of Maxigesic IV, which came in overnight, the stock lifted 16 cents per share to $3.56 at the open on the New Zealand stock exchange (NZX), up from $3.40 at yesterday's close. It has since dipped to $3.50.AFT co-founder and managing director Hartley Atkinson said they were delighted to receive the second appro...

More Markets

NZ sharemarket continues sliding, down 0.5%
Markets Market close

NZ sharemarket continues sliding, down 0.5%

The S&P/NZX 50 Index closed at 12,692.72, down 68.47 points or 0.54%.

Graham Skellern 12 Dec 2024
Spark sells remaining Connexa stake for $314m
Markets

Spark sells remaining Connexa stake for $314m

The sale will result in a $70m gain on telco's books.

Ben Moore 12 Dec 2024
Zespri on track for 'moderate increase' in volume next year
Primary Sector

Zespri on track for 'moderate increase' in volume next year

Zespri's producer vote to expand global supply passed this week.

Riley Kennedy 12 Dec 2024
Neal Barclay to exit Meridian as CEO
Markets

Neal Barclay to exit Meridian as CEO

Current CFO Mike Roan will take Barclay's spot atop Meridian.

Staff reporters 12 Dec 2024